SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?


To: Rocketman who wrote (5699)10/1/1998 10:59:00 AM
From: Vector1  Read Replies (1) | Respond to of 9719
 
Now we should buy.
--
+CollaGenex Pharma Gets FDA OK To Market Periostat >CGPI
Story 0877 CollaGenex - Periostat -2: To Treat Periodontitis >CGPI
NEWTON, Pa. (Dow Jones)--CollaGenex Pharmaceuticals Inc. (CGPI) received
Food and Drug Administration approval to market Periostat, an oral medication
for the adjunctive treatment of periodontitis.
Periodontitis is a condition that could lead to tooth loss, CollaGenex said.
In a press release Thursday, the company said it expects Periostat to be
available by prescription within six to eight weeks.
CollaGenex is a pharmaceutical company.
(END) DOW JONES NEWS 10-01-98
07:09 AM
Additional Codes (R/PA, R/US, R/USE)



To: Rocketman who wrote (5699)10/1/1998 11:01:00 AM
From: Vector1  Read Replies (2) | Respond to of 9719
 
Icos cut a deal with Lilly. The only thing holding the stock is the market. I think we should cover at 18 1/16th.
V1